India Pharma Outlook Team | Tuesday, 22 February 2022
The Drug Controller General of India (DCGI) recommended emergency use of Biological E's Covid-19 vaccine Corbevax in the 12 to 18 years age-group. "BE received the approval for restricted use in an emergency situation in adolescents aged 12 to less than 18 years based on interim results (of the ongoing phase 2/3 clinical study)," the company said in a statement. Corbevax is an RBD protein sub-unit vaccine developed
with support from the department of biotechnology (DBT) and the Biotechnology Industry Research Assistance Council under the DBT. The government has not yet begun Covid-19 jabs for the 12 to 14 years age-group in the country, which has more than 70 million adolescents.
At present, those in the 15 to 18 years age-group are eligible to receive Bharat Biotech's Covid vaccine Covaxin. On August 20, the regulator had given emergency use authorisation to a three-dose Covid-19 vaccine from Zydus Cadila, the first in India that can be given to people 12 years and above. However, this jab will be first given to adults. Corbevax could become the next choice of vaccine for children in India, people in the know said. The government plans to vaccinate children in the 12 to 14 years age-group from the end of this month or early March.
, CDSCO.jpg)
